**Core tip:** Lack of compelling methods for early diagnosis of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) disease leads to poor prognosis. The identification of more reliable markers for diagnosis of HCC with easy methodologies for HCC screening and detection in early stage is desperately required. A collection of small non-coding circulating RNAs associated with HCC related-HCV has been found to be differentially communicated and included in the pathogenesis of the disease. Thus, we can use these molecules as prospective biomarkers for HCC, with some of the miRNAs representing biomarkers for liver fibrosis progression.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is one of the first five cancers represented in the hierarchy of cancer mortality rates, causing around 500000 deaths per annum\[[@B1]\]. Patients with HCC have the least survival compared to patients with other types of cancer, and most die within a year from developing tumor\[[@B2]\]. In Egypt, HCC is the 2^nd^ leading cause of cancer-related death in males and the 5^th^ in females\[[@B3]\].

HCC incidence is on the rise. Several etiologies are the main determinants underlying the sharp increase in HCC rate, with chronic hepatitis infection (either B or C) and fatty liver disease being the most important predisposing factors. Hepatitis C virus (HCV) increases the risk of HCC development by almost 17-fold\[[@B4],[@B5]\]. During the last 10 years, Egypt showed around 2-fold increment increase in HCC development among chronic liver disease patients, mainly due to infection with HCV\[[@B6]-[@B8]\].

Multiple studies have suggested that early detection of HCC will increase the lifetime of HCC patients\[[@B9]\]. Current strategies for the diagnosis of HCC fall into two main categories: biomarker tests and imaging. Unfortunately, the diagnostic performance of these strategies is not satisfactory, especially at the early stages of disease. Currently, only 30% to 40% of patients with HCC are qualify for potential curative intervention at diagnosis, because of the lack of clinical presentation and absence of potential early identification biomarkers. Thus, the identification of new reliable markers for HCC, with high sensitivity and specificity, is of great importance\[[@B9]\].

Micro (mi)RNAs are a group of non-coding small RNAs that regulate the expression of other protein-coding RNAs, at both the transcriptional and post-transcriptional levels. It is well known that miRNAs manage every aspect of cell activities, including cell differentiation and development, metabolism, cell cycle regulation, apoptosis, immune response, and oncogenesis\[[@B10]\]. Multiple studies have demonstrated that hepatic cells express high levels of certain miRNAs to control different cell functions, with their expression levels correlating to different pathological states\[[@B11]\]. Characterized by their stability and resistance to RNase degradation, miRNAs are considered as promising biomarkers for many diseases\[[@B12],[@B13]\]. The use of miRNAs as noninvasive biomarkers is of particular interest for the diagnosis of liver diseases\[[@B14]-[@B16]\].

miRNAs profiling studies in HCC have revealed significant dysregulation for a number of miRNAs\[[@B17]-[@B19]\]. In this regard, there are several examples: miR-1269 showed elevated levels in liver of HCC/HCV patients versus healthy livers\[[@B19]\]. miR-618 and miR-650 showed elevated levels in the urine of HCV/HCC patients, with enhanced specificity reaching 75% upon use of both miRNAs in concert\[[@B20]\]; these findings suggest the promise of urinary miRNAs as biomarkers for early detection of HCC. Moreover, a recent study identified a panel of serum miRNAs that have considerable clinical value in the diagnosis of HCC following hepatitis B virus (HBV) infection\[[@B20]\].

The identification of non-invasive biomarkers for predicting patients at high risk of HCC development allows early intervention and increases the probability of successful treatment, consequently reducing mortality and disease burden. Our study aims to investigate the prospective importance of some serum miRNAs as early biomarkers for the diagnosis of HCV-related HCC.

MATERIALS AND METHODS
=====================

Patients and sample collection
------------------------------

This study included 474 HCV serum-positive Egyptian patients (224 HCC patients and 250 with chronic liver hepatitis), in addition to 84 controls (HCV-negative patients). Study subjects were recruited from the Clinical Hepatology Department, Theodor Bilhariz Research Institute. Blood samples were collected according to the ethical standards for donor approval required by the national regulatory bodies under supervision of a physician and after having signed informed consent for the use of their blood in this study. All patients were pre-diagnosed HCV antibody-positive by enzyme-linked immunosorbent assay. All samples were subjected to HCV antigen detection in serum. HCC was detected by ultrasound scan and confirmed using computed tomography (CT). Fibrosis level was calculated using Metavir scoring, from F0 representing absence of fibrosis to F4 representing cirrhosis\[[@B21]\]. All HCV cases were reported as fibrotic from F1 to F4, and routine lab tests were performed for each sample. Patients with any hepatitis other than C, or malignancy other than caused by HCV, were excluded from the study. Sex distribution among healthy controls was 56 males and 28 females, with mean age of 44 and standard deviation of 12.5 years. Control subjects had normal levels of liver enzymes and alpha-fetoprotein (AFP)\[[@B22]\].

miRNA selection
---------------

It is well known that the levels of the selected serum miRNAs are dysregulated in chronically infected patients, simply because all of the aforementioned miRNAs are cell cycle and interferon (IFN)-related, and mostly affect response to IFN therapy\[[@B23]\]. Potentiality of clinical non-invasive serum biomarkers of these miRNAs in HCC-related HCV progression is unknown till now.

RNA extraction and quantification
---------------------------------

RNA was extracted using the miRNeasy Kit (Qiagen, Germany), according to the manufacturer's protocol, and quantified using the Nanoquant Infinite M200 Microplate Reader (Tecan, Switzerland). A total of 100 ng RNA was reverse transcribed using the mi-Script RT-II Kit (Qiagen) in a reaction volume of 20 μL and subjected to 60 min incubation at room temperature, followed by 5 min incubation at 95 °C. Serum levels of different miRNAs (hsa-miR-1269, hsa-miR-125b, hsa-miR-138, hsa-miR-214-5p, hsa-miR-494, hsa-miR-375 and hsa-miR-145) were assessed using the mi-Script miRNA PCR Array (Qiagen), according to the manufacturer's procedure. The housekeeping gene miRNA SNORD68 was used as an internal control\[[@B24],[@B25]\]. All the miRNA primers, including for the housekeeping gene, were purchased from Qiagen. QuantiTect SYBR PCR reagent with miScript universal primer was used according to the manufacturer's protocol (Qiagen). Quantitative PCR amplification and analysis were achieved by Rotor-gene (Qiagen), using the following thermal cycling program: 30 min at 95 °C, then 15 s at 94 °C and 30 s at 55 °C (for 40 cycles), and finally 30 s at 70 °C. The change in miRNA expression level was calculated using the 2^-ΔΔCT^ approach and relative to healthy subjects serving as the calibrator control\[[@B26]\].

Statistical analysis
--------------------

Statistical analyses were performed by SPSS-15 (SPSS Inc, United States) and GraphPad Prism-5.0 (GraphPad, United States). Mean ± SD, or median was used to express all the data in this study. Clinical data from the three independent groups were compared using one-way ANOVA test in addition to Tukey Kramer's for multiple comparisons test and Mann-Whitney *U*-test. Log transformation was applied to AFP data to facilitate the use of parametric statistical analysis. The *χ*^2^ test was used to compare categorical data. Analysis for receiver operating characteristic (ROC) with the area under the curve (AUC) was used to evaluate the diagnostic potential of each studied miRNA. The end-point was categorizing HCC out of late fibrosis (F4) using the miRNAs in the study panel\[[@B23]\].

RESULTS
=======

Clinical aspects of HCC and HCV patients
----------------------------------------

Patients showed a significant progression from moderate fibrosis to carcinoma with older age (*P \<* 0.0001). HCC patients' serum levels of alkaline phosphatase, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, bilirubin and AFP were significantly higher (*P \<* 0.0001) than those of fibrotic groups and was associated with depletion in hemoglobin, prothrombin and albumin levels, as well as platelet count (*P \<* 0.0001). Moreover, leucocyte count did not show any significant variation among these groups, as shown in Table [1](#T1){ref-type="table"}.

###### 

Clinical data of hepatocellular carcinoma and hepatitis C virus patients

                                     **Non-malignant chronic HCV (*n* = 250)**   **HCC (*n* = 224)**   ***P* value**     
  ---------------------------------- ------------------------------------------- --------------------- ----------------- -----------
  Age (years)                        40 ± 8.6^a^                                 45 ± 6.5^c^           55 ± 9.3^e^       \< 0.0001
  ALP (IU/L)                         102.3 ± 36.9^a^                             119 ± 72.1^a^         182.5 ± 58^c^     \< 0.0001
  SGOT (IU/L)                        58 ± 18^a^                                  62.5 ± 28.2^a,b^      85.4 ± 45.2^c^    0.001
  SGPT (IU/L                         52.1 ± 18^a^                                68.46 ± 24.8^a^       120.4 ± 53.4^c^   \< 0.0001
  Bilirubin, total (mg/dL)           0.40 ± 0.17^a^                              0.43 ± 0.16^a^        0.78 ± 0.69^c^    \< 0.0009
  Bilirubin, direct (mg/dL)          0.68 ± 0.28^a^                              0.85 ± 0.37^a^        1.9 ± 1.2^c^      \< 0.0001
  Log AFP (ng/mL)                    0.49 ± 0.9^a^                               0.98 ± 0.4^a^         2.3 ± 0.97^c^     \< 0.0001
  Hemoglobin (g/dL)                  13.6 ± 1.8^a^                               14.1 ± 1.5^a^         10.7 ± 1.2^c^     \< 0.0001
  Platelet count × 10^3^ (/mm^3^)    236.5 ± 21.6^a^                             158.2 ± 52.6^c^       131.2 ± 75.5^c^   \< 0.0001
  leukocyte count × 10^3^ (/mm^3^)   6.3 ± 2.22^a^                               6.4 ± 2.41^a^         5.7 ± 2.4^a^      0.460
  Prothrombin concentration (%)      103 ± 4.7^a^                                84.4 ± 8.0^c^         69.9 ± 19.3^e^    \< 0.0001
  Albumin (g/dL)                     4.7 ± 0.8^a^                                3.9 ± 0.9^c^          3.28 ± 0.6^e^     \< 0.0001

Data are expressed as mean ± SD. ANOVA was used to analyze the clinical data. Groups with different letters show a significant difference (*P* \< 0.05), while those with same letters show no significant difference (*P* \> 0.05). AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; SGOT: Serum glutamic oxaloacetic transaminase; SGPT: Serum glutamic pyruvic transaminase.

Clinical and pathological aspects for HCC patients
--------------------------------------------------

HCC patients yielded a broad range of AFP from normal healthy to abnormal values. Healthy AFP level up to 10 ng/mL was present in 31 patients, 168 patients had AFP more than 20 ng/mL and 103 patients showed AFP more than 400 ng/mL. By CT imaging, 112 patients showed one focal lesion in liver, with 64 of them showing focal size more than 5 cm, and 48 patients showed portal vein thrombosis, as shown in Table [2](#T2){ref-type="table"}.

###### 

Clinical and pathological aspect for hepatocellular carcinoma patients

  **Factor**                              ***n***
  --------------------------------------- ---------
  AFP level                               
  Less than 20 ng/mL                      56
  Between 20 and 400 ng/mL                64
  More than 400 ng/mL                     104
  Child-Pugh grade                        
  A                                       128
  B                                       80
  C                                       16
  Barcelona Clinic Liver Cancer staging   
  0                                       0
  A                                       8
  B                                       160
  C                                       40
  D                                       16
  Focal lesions                           
  Single                                  112
  Multiple                                112
  Focal size by CT                        
  \< 3 cm                                 48
  \> 5 cm                                 64
  Thrombosis in portal vein               
  Present                                 48
  Absent                                  176

AFP: Alpha-fetoprotein; CT: Computed tomography.

Serum miRNA profile in HCC patients
-----------------------------------

Differential serum miRNA levels were measured in HCC patients and compared to healthy controls and HCV-infected patients (Mann-Whitney *U*-test). The results showed that miR-1269 and miR-494 were positively regulated in HCC patients, with median fold-change of 8.71 and 5.45 respectively compared to healthy non-infected controls (*P \<* 0.0001), while miR-125b, miR-138b, miR-214-5p, miR-375 and miR-145 were negatively regulated in HCC patients, with median fold-change of 0.51, 0.46, 0.23, 0.25 and 0.6 respectively, in comparison to healthy controls and as shown in Figure [1](#F1){ref-type="fig"}.

![Differential serum miRNA expression levels in non-infected healthy controls compared to hepatocellular carcinoma patients.](WJG-23-3864-g001){#F1}

Serum miRNAs signature throughout HCV-HCC progression
-----------------------------------------------------

Serum miRNA profiles were studied from mild fibrosis progression to HCC. The possible changes in miRNA levels from mild fibrosis to HCC were tested by Mann-Whitney *U-*test. The present data show no significant difference in levels of miRNA between mild and moderate fibrosis groups, except for miR-214-5p. Moreover, the data shows that all tested miRNAs levels were significantly different between HCC and late fibrosis (*P \<* 0.05). It was found that miR-214-5p were significantly downregulated in late fibrosis F4 compared to F3 (*P \<* 0.05) and continued the downregulation trend during HCC progression versus late fibrosis F4 (*P \<* 0.05). Furthermore, miR-375, miR-145 and miR-1269 levels were significantly different in HCC and late fibrosis F4 groups (*P \<* 0.05). Conversely, miR-125 and miR-138-5p were not affected by case progression, as shown in Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}.

![Efficacy of studied miRNAs in hepatocellular carcinoma non-malignant differentiation using receiver operating characteristics curve analysis. Hepatocellular carcinoma (HCC) (*n* = 224) and healthy control (*n* = 84).](WJG-23-3864-g002){#F2}

###### 

Diagnostic ability for studied miRNA to categorize hepatocellular carcinoma among hepatitis C virus-infected fibrotic patients and controls

  **Serum miRNA**    **AUC value**   **Sensitivity**   **Specificity**   **PPV**   **NPV**   **Accuracy**
  ------------------ --------------- ----------------- ----------------- --------- --------- --------------
  miR-214-5P                                                                                 
  HCC against ctrl   0.721           61.0%             89.0%             81.0%     75.0%     77.0%
  HCC against HCV    0.842           92.9%             75.5%             51.0%     97.5%     80.0%
  miR-494                                                                                    
  HCC against ctrl   0.813           77.0%             76%               69.0%     82.0%     76.0%
  HCC against HCV    0.631           77.0%             56%               32.0%     90.0%     60.0%
  miR-138p                                                                                   
  HCC against ctrl   0.842           96.4%             78.4%             77.1%     96.0%     86.0%
  HCC against HCV    0.642           68.2%             58.2%             34.0%     90.0%     62.0%
  miR-125b                                                                                   
  HCC against ctrl   0.702           66.7%             75.7%             66.7%     75.7%     72.0%
  HCC against HCV    0.769           92.6%             55.4%             35.7%     96.6%     63.3%
  miR-1269                                                                                   
  HCC against ctrl   0.862           96.4%             78.4%             77.1%     96.7%     86.2%
  HCC against HCV    0.691           78.6%             59.8%             34.9%     91.0%     63.8%
  miR-145                                                                                    
  HCC against ctrl   0.892           100.0%            89.2%             87.1%     100.0%    93.8%
  HCC against HCV    0.624           81.5%             51.5%             30.6%     91.4%     57.7%
  miR-375                                                                                    
  HCC against ctrl   0.741           96.4%             59.5%             63.4%     95.7%     75.4%
  HCC against HCV    0.811           96.4%             69.3%             46.6%     98.6%     75.2%

AUC: Area under curve, PPV: Positive predictive value, NPV: Negative predictive value.

Test efficacy of studied miRNAs in diagnosis
--------------------------------------------

Analysis of AUC indicated that miRNAs assessed in this study might be useful to categorize HCC cases among healthy non-malignant controls. All studied circulating miRNAs showed significance difference (*P \<* 0.0001 and 95%CI for values of AUC as 0.721, 0.813, 0.842, 0.702, 0.862, 0.892 and 0.741 for miR-214-5p, miR-494, miR-138b, miR-125b, miR-1269, miR-145 and miR-375 respectively; Figure [2](#F2){ref-type="fig"}).

Also, the diagnostic efficacy for miRNA was studied and the obtained data showed differential expression between HCV and HCC groups, which helped to categorize each group separately. Analysis using ROC curve showed that the studied miRNAs were capable of distinguishing HCC from late fibrosis, with AUC values of 0.842, 0.631, 0.642, 0.769, 0.691, 0.624 and 0.811 for miR-214-5p, miR-494, miR-138b, miR-125b, miR-1269, miR-145 and miR-375 respectively, with 95%CI and *P*-value less than 0.001 (Figure [3](#F3){ref-type="fig"}). The accuracy, sensitivity and specificity for each studied miRNA were investigated to diagnostically discriminate HCC among HCV fibrotic patients or normal healthy controls and this result is presented in Table [3](#T3){ref-type="table"}.

![Efficacy of studied miRNAs in hepatocellular carcinoma, hepatitis C virus categorization using receiver operating characteristics curve analysis. Hepatocellular carcinoma (*n* = 224) and hepatitis C virus (*n* = 250). AUC: Area under the curve.](WJG-23-3864-g003){#F3}

Regression analysis for studied miRNA
-------------------------------------

Univariate and multivariate logistic regression analyses were calculated to determine the possible association of the studied miRNAs with diagnosis of HCV-related HCC progression. Levels of expression for miR-214-5p, miR-125b, miR-1269 and miR-375 were found in univariate analysis to be a significant possible predictor of HCC diagnosis, so that they may serve as a possible miRNA panel. Logit (*P*) = -0.21-1.123_miR-214-5p-0.076_miR-125b + 0.58_miR-1269 + 0.046_miR-375 was used to formulate the ROC curve. The miRNA panel's diagnostic efficacy was assessed by ROC analysis, and showed AUC of 0.938 with 95%CI specificity = 92%, sensitivity = 97.01% and accuracy = 92.3%. This panel can categorize HCC cases among healthy controls (AUC = 0.95 with 95%CI specificity = 96.9%, sensitivity = 83.2% and accuracy = 86.8%), HCV early fibrotic patients (AUC = 0.945 with 95%CI specificity = 94.3%, sensitivity = 96.7% and accuracy = 95.1%) and the late fibrotic groups (AUC = 0.99 with 95%CI, specificity = 98.3%, sensitivity = 98.7%, accuracy = 98.4%). Comparison of each of the studied miRNAs' AUC data against the miRNA panel indicated that the panel provided superior discrimination for HCC, either from nonmalignant controls and HCV fibrotic patients. The data is listed in Table [4](#T4){ref-type="table"} and shown in Figure [4](#F4){ref-type="fig"}.

###### 

Regression analysis of the miRNAs studied

                          **Coefficient**   **Standard error**   ***P* value**
  ----------------------- ----------------- -------------------- ---------------
  Univariate analysis                                            
  miR-214-5p              -0.570            0.105                \< 0.0001
  miR-494                 -0.005            0.025                0.825
  miR-125b                -0.064            0.013                \< 0.0001
  miR-1269                0.184             0.044                \< 0.0001
  miR-145                 0.0021            0.011                0.844
  miR-375                 0.066             0.011                \< 0.0001
  miR-138b                0.0019            0.013                0.852
  Multivariate analysis                                          
  miR-214-5p              -1.116            0.229                \< 0.0001
  miR-125b                -0.076            0.028                0.004
  miR-1269                0.569             0.121                \< 0.0001
  miR-375                 0.052             0.013                0.002
  Constant                -0.240                                 

![Diagnostic activity of the panel of miRNAs studied.](WJG-23-3864-g004){#F4}

Comparison of the miRNA panel with AFP using ROC curve analysis
---------------------------------------------------------------

The AUC of AFP for each study group was assessed using the patients' serum samples. AFP demonstrated a significant accurate discrimination between HCC and nonmalignant controls, HCV patients, and the late fibrotic groups with AUC values of 0.963, 0.921 and 0.888 respectively. AFP showed 100%, 96% and 90% specificity, in addition to 80% sensitivity to discriminate HCC from nonmalignant controls, the HCV group, and the late fibrosis groups respectively, with cut-off of \> 20 ng/mL. However, at the AFP cut-off level of \> 400 ng/mL, which is considered diagnostic for HCC, AFP showed specificity of 100%, 98% and 96%, and sensitivity reached 46% for the same conditions. Therefore, AUC was studied for the miRNA panel against AUC for AFP, and the result demonstrated no significant difference among them. Difference amid areas in the nonmalignant group was 0.019, *P =* 0.476 and difference amid areas in HCV groups was 0.024, *P =* 0.261; conversely, difference amid areas in late fibrotic groups was 0.083 (*P =* 0.034), as shown in Figure [5](#F5){ref-type="fig"}.

![Comparison between miRNA panel and alpha-fetoprotein using receiver operating characteristic curve. AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.](WJG-23-3864-g005){#F5}

Circulating miRNAs' associations with clinical and pathological HCC groups
--------------------------------------------------------------------------

In the investigation of HCC among portal vein thrombosis patients (*n =* 48) it was found that miR-214-5p and miR-375 expression were significantly elevated compared to normal controls (median change: 25%-75%, *P =* 0.0001). There was no strong relation found for the effect of miRNAs on either number of focal lesions nor diameter of the tumor. In addition, miR-145 was positively correlated with HCV viral load (Pearson *r* = 0.574, *P =* 0.001).

Serum miRNAs' correlation in the HCC study group
------------------------------------------------

There was significant promising association between the HCC group and all assessed miRNAs. miR-214-5p was correlated significantly with miR-138b (*r* = 0.649, *P \<* 0.0002), miR-125b (*r* = 0.518, *P =* 0.005), miR-1269 (*r* = 0.621, *P =* 0.0005) and miR-145 (*r* = 0.449, *P =* 0.009). miR-494 was correlated with miR-138b (*r* = 0.471, *P =* 0.008), miR-1269 (*r* = 0.418, *P =* 0.021) and miR-145 (*r* = 0.538, *P =* 0.003). miR-138b was also correlated with miR-125b (*r* = 0.685, *P \<* 0.0001), miR-1269 (*r* = 0.862, *P \<* 0.0001) and miR-145 (*r* = 0.521, *P =* 0.006). miR-1269 was also correlated with miR-125b (*r* = 0.602, *P =* 0.001) and miR-145 (*r* = 0.453, *P =* 0.019). miR-145 was correlated with miR-375 (*r* = 0.460, *P =* 0.038), as shown in Table [5](#T5){ref-type="table"}.

###### 

Significant relations among enrolled circulating miRNAs in hepatocellular carcinoma patients

                  **miR-138b**    **miR-494**     **miR-145**     **miR-375**     **miR-214-5p**   **miR-1269**   **miR-125b**
  --------------- --------------- --------------- --------------- --------------- ---------------- -------------- --------------
  miR-138b                        *r* = 0.471     *r* = 0.521     NS              *r* = 0.649      *r* = 0.862    *r* = 0.685
  *P* = 0.008     *P* = 0.006     *P* \< 0.0002   *P* \< 0.0001   *P* \< 0.0001                                   
  miR-494         *r* = 0.471                     *r* = 0.538     NS              NS               *r* = 0.418    NS
  *P* = 0.008     *P* = 0.003     *P* = 0.021                                                                     
  miR-145         *r* = 0.521     *r* = 0.538                     *r* = 0.460     *r* = 0.449      *r* = 0.453    NS
  *P* = 0.006     *P* = 0.003     *P* = 0.038     *P* \< 0.009    *P* = 0.019                                     
  miR-375         NS              NS              *r* = 0.460                     *r* = 0.884      NS             NS
  *P* = 0.038     *P* \< 0.0001                                                                                   
  miR-214-5p      *r* = 0.649     NS              *r* = 0.449     *r* = 0.884                      *r* = 0.621    *r* = 0.518
  *P* \< 0.0002   *P* \< 0.009    *P* \< 0.0001   *P* = 0.0005    *P* = 0.005                                     
  miR-1269        *r* = 0.862     *r* = 0.418     *r* = 0.453     NS              *r* = 0.621                     *r* = 0.602
  *P* \< 0.0001   *P* = 0.021     *P* = 0.019     *P* = 0.0005    *P* = 0.001                                     
  miR-125b        *r* = 0.685     NS              NS              NS              *r* = 0.518      *r* = 0.602    
  *P* \< 0.0001   *P* = 0.005     *P* = 0.001                                                                     

*r* is the Spearman rho coefficient. NS: Non-significant.

DISCUSSION
==========

One of the major challenges for HCC diagnosis in the early stage is the absence of reliable biomarkers, which strengthen urgent demand for efficient profitable early diagnostic assays. In our current investigation, it is revealed that the expression level of all the studied circulating miRNAs differed significantly between HCV patients and HCV/HCC patients when compared to healthy controls, suggesting miRNA biomarker activity against HCC progression. In addition, individual miRNA could be used to discriminate the HCC from HCV fibrotic patient from the healthy control. The multivariate analysis showed a panel of serum miRNAs (miR-214-5p, miR-375, miR-125b and miR-1269) that has accurate diagnostic efficacy against HCC progression. Also, it showed superior diagnostic accuracy over AFP in discriminating the late fibrosis group, which has a significant tendency to develop HCC. In addition, the data for the studied miRNA panel showed significantly higher diagnostic accuracy than has been formerly reported for AFP (specificity: 76%-94% and sensitivity: 39%-65%)\[[@B27]\]. More than 35% of HCC patients are missed by early AFP testing, besides its conflicting elevation in both chronic hepatitis and cirrhotic patients\[[@B27]\], which highlights the greater reliability of the studied miRNAs for early diagnosis and fortifies its therapeutic and serological tumor markers feature, especially for HCC control.

The present data confirm that the tested serum miRNAs significantly correlated with HCC-HCV groups and suggest their possible role in HCV pathogenesis. Supportive for the latter possibility, HCV proteins have been shown to regulate cell cycle behavior and apoptosis in HCC patients through alteration of cellular expression of miRNAs, especially in cells carrying the HCV infectious strand\[[@B28]\]. Circulating miR-375 and miR-214-5p were shown to be negatively regulated in HCC compared to either healthy controls or HCV fibrotic patients\[[@B28]\]. Also, miR-375 was reported as negatively regulated in HCC patients compared to HBV-infected patients\[[@B29]\], and in another report negative regulation was shown in the serum and tissues of HCC patients compared to nonmalignant controls\[[@B28],[@B30]\]. Downregulation of miR-375, on the other hand, promotes tumor formation through upregulation of YAP1 and AEG-1, both of which induce cell growth (tissue invasion), and of IGF1R, which also induces cell growth (metastasis)\[[@B30]\]. miR-214-5p plays critical roles in the activation of stellate cells and, in turn, the progression of fibrotic liver\[[@B31]\], besides acting as a negative regulator for HCC metastasis by regulating fibroblast growth factor receptor 1 expression\[[@B32]\]. In the current investigation, we showed that elevated levels of circulating miR-375 were also correlated with portal vein thrombosis, especially in the HCC group, indicating the importance of miR-375 in HCC progression. miR-375 is involved in the Wnt/β-catenin pathway and its downregulation in patients with HCC is mediated by β-catenin\[[@B33]\]. So, both miR214-5p and miR-375 have a possible association with the presence of HCC satellite nodules, recurrence of HCC and survival rate after transplantation. All of these issues strengthen the possible prognostic importance of miR-375 and 214-5p in HCC.

Circulating miR-494 and miR-1269 were upregulated in HCC patients compared to controls. miR-494 was significantly lower in the HCV group compared to the HCC group, while miR-1269 was significantly higher in the HCC patients than in the HCV patients. Serum miR-214-5p, miR-375 and miR-145 were downregulated in HCC compared to controls or HCV groups. Similarly, serum miR-125b and miR-138-5p were downregulated in the HCC group and the HCV group compared to the control group, miR-1269 was also upregulated in HCC patient serum compared to nonmalignant healthy control serum. It has been reported that miR-1269a is a potential marker for making adjuvant chemotherapy decisions for colorectal cancer patients, and a potential therapeutic target to deter metastasis\[[@B34]\].

Dysregulation has been shown for some serum miRNAs in HCC patient serum and tissue, *i.e*., miR-125b was downregulated in HCC tissues compared to adjacent non-cancerous tissue\[[@B35]\]. These contradictory results reveal that the same miRNA can play dual tumor oncogenic and suppressor roles in the progression of cancer. Remarkably, miR-214 was downregulated throughout tumor progression, relating to metastasis in HCC; this downregulation stimulates tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma\[[@B36]\]. miR-125b also suppresses HCC invasion or metastasis *via* downregulation of VEGF\[[@B37]\]. This process in the endothelial cells clearly promotes vascularization and angiogenesis, and its downregulation was correlated with HCC deterioration\[[@B38]\]. Conversely, miR-1269\[[@B39]\] and miR-494 were elevated in HCC and negatively affected the anti-tumor immune response\[[@B40]\].

In the current study, it was found that the expression levels of 3 from the 7 studied serum miRNAs were matched with their tissue levels (hepatic) in HCC compared to healthy controls\[[@B35],[@B41],[@B42]\]; however, up to the time this work was begun, no studies had been performed to measure the expression levels of the studied miRNAs in HCC tissue against normal. miR-122 was downregulated in HCC cell lines and hepatic tissue\[[@B43]\] but upregulated in HCC serum patients\[[@B27],[@B44]\], which suggests that miRNAs secreted from cells could be a vital part of circulating miRNA expression\[[@B45]\]. During liver injury, exosome secretion increases circulating miR-122, causing its hepatic expression to decrease\[[@B46]\]. Conversely, miRNAs reported as raised during liver injury have also shown serum level reduction\[[@B47]\], which has been reported as involving miRNAs, with HCC tissue level elevation and HCC serum level decline\[[@B48]\].

The significant variability between studies on the various miRNA levels in HCC reflects the antithetical mechanism regulating miRNA expression. For example, miR-375 enhances p21 expression and miR-214 controls p53 and XBP1, so that both miRNAs control tumor progression; mechanisms of liver injuries that activate p53 may be upregulated by miR-214 and miR-375\[[@B48],[@B49]\]. The differences between different reports may be due to the variable procedures used for investigation, beginning with ways of collecting samples and ranging to various detection protocols and methods of data analysis\[[@B50]\]. It is noteworthy that the etiology of the disease is a mandatory matter, as HBV-related HCC differs from HCV-related HCC in the molecular mechanisms of miRNA dysregulation\[[@B51]\].

Briefly, impact of circulating miRNAs in cancer progression is now well established; often, the involved pathways are cell proliferation, differentiation, migration, invasion and angiogenesis, all of which are frequently dysregulated by cancer cell mechanisms and so their functions contrast basically according to tissue types. For example, miR-21 (oncomiR) expression increases growth rate of cancer (tissue invasion) through targeting of many tumor suppressor mRNAs, such as PTEN and PDCD4\[[@B52],[@B53]\], while miR-214 targets many oncogenic mRNAs to limit cancer cell proliferation, such as CD44 and CDK1\[[@B48]\]. HCC progression includes several stages, but almost all HCV patients experience progression of fibrosis to cirrhosis, and HCC\[[@B54]\].

In the current study, a reduction in albumin and prothrombin (which represent liver synthetic function) was shown during liver disease progression, but we found no correlation with the circulating miRNAs studied. miRNA expression level is dysregulated in the fibrotic liver, which provides evidence that miRNAs are affected by the progression of liver fibrosis\[[@B51]\]. In the current study, miR-214-5p and miR-145 were positively regulated in fibrotic patients, as compared to healthy controls, with up to 5.2- and 3.8-fold increases respectively and with significant reduction during cirrhosis progression and downregulation in HCC patient serum. The latter can be attributed to the release of miRNA from HCV-inflamed hepatocytes into the circulation, followed by a dramatic decline in their level after late fibrosis due to complete damage of hepatocytes and the presence of cirrhotic tissue with accumulation of extracellular matrix\[[@B55]\].

A key player in fibrosis progression is the activation of hepatic stellate cells, which correlates with deregulation of specific miRNA through regulation of various fibrogenic signaling pathways\[[@B56]\]. It is likely that miR-214-5p and miR-145 is associated with inflammation-fibrosis in HCV-related HCC. Most of the previous publications have reported that miRNAs cannot be differentially expressed during different fibrosis-stages\[[@B48]\]. Conversely, miR-214-5p has been demonstrated to be differentially expressed during fibrosis progression, until HCC, with serum miR-145 being elevated during the progression of fibrosis in chronic HCV\[[@B57]\]. These findings could strengthen the probability of using miR-145 as a reliable prognostic marker, especially for fibrosis progression interpretation.

In the current study, the selected serum miR-214-5p was found to be correlated with fibrosis progression and it showed significant positive correlation with Barcelona Clinic Liver Cancer staging score and Child-Pugh grade, which is used to define HCC for various treatment protocols and which might outline the effectiveness of serum miR-214-5p in assessing severity of HCC for possible therapeutic interferences.

Earlier publications have reported evaluations of circulating miRNAs as HCC biomarkers compared to healthy nonmalignant controls and chronic HCV or fibrosis\[[@B9],[@B12],[@B15],[@B19],[@B25],[@B44],[@B58]-[@B60]\], but yielded insufficient discovery of miRNAs as effective biomarkers. Our study presented a panel of four miRNAs characterized by high specificity for HCC, supporting its clinical impact on diagnosis of HCV-related HCC. Moreover, most of the previous studies investigated HCC of mixed etiologies, not were not specific for HCV-related HCC. Another drawback to the existing literature is that there are limited studies evaluating the circulating miRNAs as reliable candidate biomarkers during HCV fibrosis progression to HCC.

Our study detected a pattern of serum miRNAs during the progression of HCV fibrosis to HCC. The evaluated miRNAs had significant variation from early fibrosis to late fibrosis to the formation of HCC, and the results led us to propose them as possible biomarkers for liver disease progression, especially for miR 214-5p and miR-145. Despite our findings, the miR-1269 levels were not fully explained, especially for the correlation from fibrosis progression to HCC, and additional studies are mandatory to validate this panel of miRNA in an independent patient cohort and to validate its outcome significantly in HCC prognosis. Moreover, the inferences of this panel as targets for HCC therapy and application in urine diagnosis will require detailed study.

In conclusion, the assessed panel of serum miRNAs (miR-214-5p, miR-375, miR-1269 and miR-125b) could be used to discriminate HCV-related HCC patients from late fibrotic patients, potentiating its practicality in uses as early prognostic biomarkers of HCC, especially for high-risk individuals. The present study identified a panel of four serum miRNAs that have an elevated accuracy for HCC and promising clinical impact on prognosis of HCV-related HCC. But, there is a need for further studies to assure efficacy of this panel in an independent patient cohort study and different population (other than Egyptian patients). Most of circulating miRNAs are fibrosis-stage independent; however, miR-214-5p showed significant downregulation during liver fibrosis progression, *i.e*., cirrhosis ending with HCC. The results suggest that serum miR-145 monitoring might be a possible diagnostic tool for progression of fibrosis to HCC. The studied miRNAs panel showed significant correlation with HCC patients. Finally, the association between miR-214-5p and miR-375 in portal vein thrombosis and cancer stage scores supported their prognostic value in HCC progression.
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The authors confirm data of previous epidemiological studies that suggest miRNAs as viable prognosis markers for HCV-related HCC progression. Also, this study sheds light on a new panel of miRNAs for early HCC prognosis.
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miRNA panel should be added to the HCV-related HCC prognosis markers involved in HCC disease progression for the Egyptian population.
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